Efgartigimod (Vyvgart / Vyvgart Hytrulo) targets the FcRn receptor to reduce pathogenic IgG antibodies by 70–80%. This mechanism is uniquely suited to the majority of antibody-mediated autoimmune diseases. argenx has validated the platform in gMG, CIDP, and pemphigus vulgaris — three diseases with distinct autoantibody profiles but the same core mechanism. The pipeline targets 20+ additional diseases, each representing a $1–5B+ commercial opportunity. No other company has executed this multi-indication FcRn strategy at scale.
CIDP (chronic inflammatory demyelinating polyneuropathy) affects ~50,000 US patients. Standard of care — IVIG infusions requiring monthly hospital visits — is inconvenient, expensive ($30–60K/year), and poorly tolerated. Vyvgart Hytrulo (SC) demonstrated superiority in the ADHERE trial with 61% relapse-free vs. 34% for placebo, plus IVIG superiority signals. argenx is capturing ~30% of treated patients within 18 months of launch, with market share still accelerating. We model CIDP reaching $3.5B in peak annual revenue by 2029.
Q1 2026 revenue of $1.30B (+63% YoY) marked the 17th consecutive quarter of double-digit revenue growth — the longest streak in large-cap biotech. Revenue breakdown: gMG ~$560M, CIDP ~$590M, PV ~$100M, other ~$50M. CIDP is now the largest revenue contributor, ahead of gMG, and its growth rate is accelerating (Q1 +92% YoY). The CIDP trajectory mirrors early Vyvgart gMG launch but in a larger, less-penetrated market. Combined, these dynamics support $6.0B FY26E revenue and $24B+ FY28E peak sales estimates.
Myositis (ADHERE-2 trial): dermatomyositis + polymyositis Ph3 data in Q4 2026 — $5B+ addressable market if successful. MMN (multifocal motor neuropathy) Ph3 readout in H1 2027 — no approved therapies. Seronegative gMG sNDA filing in H2 2026 expands gMG label to ~20% of patients currently excluded. Bullous pemphigoid NDA under FDA review — estimated Q3 2026 approval. Each catalyst is binary and significantly de-risked by the validated mechanism.
| USD $M | FY23A | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|---|
| REVENUE BREAKDOWN | ||||||
| gMG (Vyvgart / Hytrulo) | 480 | 950 | 1,760 | 2,820 | 3,200 | 3,600 |
| CIDP (Vyvgart Hytrulo) | — | 420 | 1,120 | 2,640 | 3,660 | 4,560 |
| Pemphigus Vulgaris (PV) | — | 120 | 210 | 360 | 540 | 720 |
| Bullous Pemphigoid & Other | — | 40 | 80 | 180 | 400 | 620 |
| Total Revenue | 480 | 1,530 | 3,170 | 6,000 | 7,800 | 9,500 |
| YoY Growth | +92% | +219% | +107% | +89% | +30% | +22% |
| PROFITABILITY | ||||||
| Gross Profit | 378 | 1,255 | 2,662 | 5,040 | 6,630 | 8,170 |
| Gross Margin % | 78.8% | 82.0% | 84.0% | 84.0% | 85.0% | 86.0% |
| Research & Development | (680) | (820) | (980) | (2,000) | (2,340) | (2,660) |
| SG&A (Selling & Commercial) | (480) | (820) | (1,050) | (1,400) | (1,560) | (1,800) |
| EBIT (Operating Income) | (782) | (385) | 632 | 1,640 | 2,730 | 3,710 |
| EBIT Margin % | nm | nm | 19.9% | 27.3% | 35.0% | 39.1% |
| Interest Income (Net Cash) | 80 | 140 | 190 | 280 | 400 | 450 |
| Income Tax (~18%) | — | — | (147) | (344) | (565) | (748) |
| Net Income (GAAP) | (702) | (245) | 675 | 1,576 | 2,565 | 3,412 |
| EPS (Diluted, GAAP) | ($10.78) | ($3.76) | $10.38 | $24.21 | $39.42 | $52.42 |
| Diluted Shares (M) | 65.1 | 65.1 | 65.0 | 65.1 | 65.1 | 65.1 |
| USD $M | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| BALANCE SHEET — KEY ITEMS | |||||
| Cash, Equivalents & Investments | 2,800 | 3,900 | 5,600 | 7,950 | 11,100 |
| Accounts Receivable | 380 | 720 | 1,350 | 1,750 | 2,140 |
| Total Current Assets | 3,580 | 5,080 | 7,540 | 10,400 | 14,100 |
| Total Assets | 4,950 | 6,400 | 9,200 | 12,400 | 16,600 |
| Total Debt | — | — | — | — | — |
| Total Equity (Book Value) | 3,950 | 5,150 | 7,400 | 10,500 | 14,400 |
| Net Cash Per Share | $43.02 | $59.92 | $86.02 | $122.12 | $170.51 |
| CASH FLOW STATEMENT | |||||
| Cash From Operations (CFO) | (185) | 820 | 1,790 | 2,620 | 3,560 |
| Capital Expenditures | (80) | (120) | (190) | (230) | (270) |
| Free Cash Flow (FCF) | (265) | 700 | 1,600 | 2,390 | 3,290 |
| FCF Margin % | nm | 22.1% | 26.7% | 30.6% | 34.6% |
| Share Repurchases / Dividends | — | — | — | — | — |
| Net Change in Cash | 420 | 1,100 | 1,700 | 2,350 | 3,150 |
| Company | Ticker | Mkt Cap | Rev Growth | EBIT Margin | EV/Rev FY27E | P/E FY27E | Rating |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | VRTX | $118B | +15% | 42% | 9.0x | 27x | BUY |
| Regeneron Pharmaceuticals | REGN | $62B | +12% | 38% | 6.8x | 20x | BUY |
| UCB SA (CIDP competitor) | UCB | $35B | +18% | 24% | 4.2x | 19x | HOLD |
| J&J Immunology (nipocalimab) | JNJ | $380B | +6% | 28% | n/a | 16x | HOLD |
| argenx SE | ARGX | $40.4B | +30% | 35.0% | 5.3x | 24.1x | BUY ★ |
argenx has accomplished what few biotechs achieve: building a validated multi-indication platform that is reshaping how severe autoimmune diseases are treated. Vyvgart Hytrulo's FcRn mechanism has been proven across gMG, CIDP, and pemphigus vulgaris — a triumvirate of commercially successful approvals that generates $6.0B in FY26E revenue and is still accelerating. The CIDP trajectory alone — capturing hospital-based IVIG patients who gain access to a convenient once-weekly subcutaneous injection — mirrors the early days of Dupixent and Jardiance in terms of structural market displacement. At 25.6x FY26E EPS, the stock trades at a 20–30% discount to comparable large-cap immunology franchises despite 3x the revenue growth rate. The pipeline (myositis Ph3, MMN Ph3, BP approval, seronegative gMG) provides multiple near-term binary catalysts with asymmetric risk/reward. Our analysis assigns $950 base-case PT on 24x FY27E EPS of $39.42. Price Target: $950 (BUY). Overweight. The 2026 biotech conviction idea.